Surrozen Inc (SRZN) - News Archive

Surrozen Secures $175 Million for Eye Disease Therapeutics in Oversubscribed OfferingSurrozen Inc. a biopharmaceutical company focused on developing selective Wnt mimetic therapeutics to address serious eye diseases, an...

In an exciting development for the field of respiratory diseases, Surrozen Inc. and TCGFB, Inc. have announced a strategic research collaboration aimed at developing transformative therapies for idiopathic pulmonary fib...

Enhancing Wnt Signaling: Surrozen s SWEETS Platform Shows Potential in Groundbreaking Study In a recent publication in eLife, Surrozen, a biotechnology company, has unveiled its proprietary SWEETS (Selective Wnt Enhance...

At the prestigious 2024 European Association for the Study of the Liver (EASL) conference held in Milan, Surrozen Inc., a front-runner in biopharmaceutical innovation, presented groundbreaking preliminary results from i...

Alcohol-Associated Hepatitis (AAH) is a life-threatening condition affecting individuals who consume excessive amounts of alcohol. It is characterized by inflammation and damage to the liver, leading to liver failure in...

:The Associations for Research in Vision and Ophthalmology (ARVO) Annual Meeting witnessed groundbreaking presentations by Surrozen, shedding light on the incredible potential of antibody-based Wnt mimetics in the treat...

Surrozen Publishes Study in nRespiratory Researchn Demonstrating the Promise of a Wnt Mimetic Antibody in Treating Pulmonary FibrosisPulmonary fibrosis, a progressive and debilitating lung disease characterized by the f...

In a recent corporate update, biopharmaceutical company Surrozen announced a strategic prioritization of its clinical programs to concentrate on the development of SZN-043, a potential treatment for Alcohol-Associated H...